CMS is forcing Medicare drug plans to cover "substantially all" brands in six key classes through 2007. That's good for some big brands but it could hasten the end of the private market system for Part D. The decision means that drug marketers in the six protected classes--antipsychotics, antidepressants, anticonvulsants, antiretrovirals, antineoplastics, and immunosuppressants-will continue to hold the upper hand in discount negotiations with managed care plans for about eighteen months, until the wrangling for 2008 plan prices begins in mid-2007.
Cole Werble
Round two in the struggle between Medicare private plans and pharma over the pricing of drugs in six key therapeutic...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
